home / stock / pcsa / pcsa short
Short Information | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 15,508 |
Total Actual Volume | 22,719 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 14 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 775 |
Average Short Percentage | 67.47% |
Is there a PCSA Short Squeeze or Breakout about to happen?
See the PCSA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-23-2020 | $9.99 | $9.94 | $9.99 | $9.74 | 800 | 800 | 100% |
09-22-2020 | $10.1 | $10.1 | $11 | $10.1 | 2,100 | 900 | 42.86% |
09-21-2020 | $8.19 | $9.39 | $9.39 | $8.19 | 2,280 | 2,280 | 100% |
09-18-2020 | $8.19 | $8.39 | $8.39 | $8.19 | 1,600 | 1,600 | 100% |
09-17-2020 | $8 | $8 | $8 | $7.805 | 1,500 | 1,076 | 71.73% |
09-16-2020 | $8.45 | $8.05 | $8.45 | $8.05 | 1,000 | 500 | 50% |
09-14-2020 | $8 | $8.45 | $8.45 | $8 | 1,814 | 820 | 45.2% |
09-08-2020 | $7.7 | $7.6 | $7.7 | $7.6 | 200 | 100 | 50% |
09-03-2020 | $8 | $8 | $8 | $8 | 184 | 180 | 97.83% |
09-02-2020 | $7.95 | $7.95 | $7.95 | $7.95 | 1,050 | 1,000 | 95.24% |
09-01-2020 | $7.9 | $7.9 | $8 | $7.9 | 302 | 2 | 0.66% |
08-27-2020 | $8.15 | $8.25 | $8.25 | $8.15 | 200 | 100 | 50% |
08-21-2020 | $8.19 | $8.19 | $8.19 | $8.19 | 250 | 150 | 60% |
07-22-2020 | $8.5 | $8.5 | $8.5 | $8.5 | 900 | 900 | 100% |
07-17-2020 | $8 | $8 | $8 | $8 | 200 | 200 | 100% |
07-16-2020 | $7 | $8 | $8 | $7 | 805 | 400 | 49.69% |
07-13-2020 | $6.71 | $6.5 | $6.71 | $6.255 | 4,300 | 2,800 | 65.12% |
06-09-2020 | $6.5 | $7 | $7 | $6 | 1,286 | 300 | 23.33% |
05-29-2020 | $8 | $8 | $8 | $8 | 900 | 900 | 100% |
05-13-2020 | $8.01 | $6.0001 | $8.01 | $6.0001 | 1,048 | 500 | 47.71% |
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company today announced that it has named Steven Cha, M.D. as senior vice president of clinical research. In the newly cre...
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemother...
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. ...